Antiemetics

• Verfasst von: Hesketh, Paul [VerfasserIn]
• Verfasst von: Kris, Mark G. [VerfasserIn]
• Verfasst von: Basch, Ethan [VerfasserIn]
• Verfasst von: Bohlke, Kari [VerfasserIn]
• Verfasst von: Barbour, Sally Y. [VerfasserIn]
• Verfasst von: Clark-Snow, Rebecca Anne [VerfasserIn]
• Verfasst von: Danso, Michael A. [VerfasserIn]
• Verfasst von: Dennis, Kristopher [VerfasserIn]
• Verfasst von: Dupuis, L. Lee [VerfasserIn]
• Verfasst von: Dusetzina, Stacie B. [VerfasserIn]
• Verfasst von: Eng, Cathy [VerfasserIn]
• Verfasst von: Feyer, Petra C. [VerfasserIn]
• Verfasst von: Jordan, Karin [VerfasserIn]
• Verfasst von: Noonan, Kimberly [VerfasserIn]
• Verfasst von: Sparacio, Dee [VerfasserIn]
• Verfasst von: Lyman, Gary H. [VerfasserIn]
• Titel: Antiemetics
• Titelzusatz: ASCO guideline update
• Verf.angabe: Paul J. Hesketh, Mark G. Kris, Ethan Basch, Kari Bohlke, Sally Y. Barbour, Rebecca Anne Clark-Snow, Michael A. Danso, Kristopher Dennis, L. Lee Dupuis, Stacie B. Dusetzina, Cathy Eng, Petra C. Feyer, Karin Jordan, Kimberly Noonan, Dee Sparacio, and Gary H. Lyman
• E-Jahr: 2020
• Jahr: July 13, 2020
• Umfang: 16 S.
• Fussnoten: Gesehen am 29.10.2020
• Titel Quelle: Enthalten in: Journal of clinical oncology
• Ort Quelle: Alexandria, Va. : American Society of Clinical Oncology, 1983
• Jahr Quelle: 2020
• Band/Heft Quelle: 38(2020), 24, Seite 2782-2797
• ISSN Quelle: 1527-7755
• DOI: doi:10.1200/JCO.20.01296
• Datenträger: Online-Ressource
• Sprache: eng
• K10plus-PPN: 1737379449

Abstract

Purpose: To update the guideline to include new anticancer agents, antiemetics, and antiemetic regimens and to provide recommendations on the use of dexamethasone as a prophylactic antiemetic in patients receiving checkpoint inhibitors (CPIs). Methods: ASCO convened an Expert Panel and updated the systematic review to include randomized controlled trials (RCTs) and meta-analyses of RCTs published between June 1, 2016, and January 24, 2020. To address the dexamethasone and CPI question, we conducted a systematic review of RCTs that evaluated the addition of a CPI to chemotherapy. Results: The systematic reviews included 3 publications from the updated search and 10 publications on CPIs. Two phase III trials in adult patients with non-small-cell lung cancers evaluating a platinum-based doublet with or without the programmed death 1 (PD-1) inhibitor pembrolizumab recommended that all patients receive dexamethasone as a component of the prophylactic antiemetic regimen. In both studies, superior outcomes were noted in the PD-1 inhibitor-containing arms. Other important findings address olanzapine in adults and fosaprepitant in pediatric patients. Recommendations: Recommendations for adults are unchanged with the exception of the option of adding olanzapine in the setting of hematopoietic stem cell transplantation. Dosing information now includes the option of a 5-mg dose of olanzapine in adults and intravenous formulations of aprepitant and netupitant-palonosetron. The option of fosaprepitant is added to pediatric recommendations. There is no clinical evidence to warrant omission of dexamethasone from guideline-compliant prophylactic antiemetic regimens when CPIs are administered to adults in combination with chemotherapy. CPIs administered alone or in combination with another CPI do not require the routine use of a prophylactic antiemetic. Additional information is available at www.asco.org/supportive-care-guidelines.